Sangamo Therapeutics (SGMOQ) EPS (Basic) (2010 - 2025)
Sangamo Therapeutics (SGMOQ) posted quarterly EPS (Basic) of -$0.13 for Q4 2025, down 15.13% year-over-year from -$0.16 in Q4 2024, and down 16.34% quarter-over-quarter from -$0.11 in Q3 2025.
Sangamo Therapeutics (SGMOQ) EPS (Basic) (2010 - 2025) Analysis & Trends
Sangamo Therapeutics' EPS (Basic) history runs 16 years deep, the most recent figure standing at -$0.13 for Q4 2025.
- In Q4 2025, EPS (Basic) fell 15.13% year-over-year to -$0.13; the TTM figure through Dec 2025 stood at -$0.44 (up 10.82% YoY), while the FY2025 annual figure was -$0.44, up 9.65% from the prior year.
- EPS (Basic) for Q4 2025 stood at -$0.13, down from -$0.11 in the prior quarter.
- The five-year high for EPS (Basic) was $0.13 in Q1 2023, with the low at -$0.66 in Q2 2023.
- The 5-year median for EPS (Basic) is -$0.28 (2022), against an average of -$0.25.
- The sharpest annual moves came in 2021 and 2023: EPS (Basic) slumped 2968.83% in 2021, then surged 141.69% in 2023.
- Sangamo Therapeutics' EPS (Basic) stood at -$0.26 in 2021, then fell by 29.75% to -$0.34 in 2022, then slipped by 2.7% to -$0.35 in 2023, then soared by 66.44% to -$0.12 in 2024, then retreated by 15.13% to -$0.13 in 2025.
- Business Quant data shows SGMOQ's EPS (Basic) at -$0.13 in Q4 2025, -$0.11 in Q3 2025, and -$0.08 in Q2 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -0.13 |
| Sep 30, 2025 | -0.11 |
| Jun 30, 2025 | -0.08 |
| Mar 31, 2025 | -0.14 |
| Dec 31, 2024 | -0.12 |
| Sep 30, 2024 | 0.05 |
| Jun 30, 2024 | -0.18 |
| Mar 31, 2024 | -0.27 |
| Dec 31, 2023 | -0.35 |
| Sep 30, 2023 | -0.59 |
| Jun 30, 2023 | -0.66 |
| Mar 31, 2023 | 0.13 |
| Dec 31, 2022 | -0.34 |
| Sep 30, 2022 | -0.34 |
| Jun 30, 2022 | -0.29 |
| Mar 31, 2022 | -0.30 |
| Dec 31, 2021 | -0.26 |
| Sep 30, 2021 | -0.33 |
| Jun 30, 2021 | -0.33 |
| Mar 31, 2021 | -0.32 |